title: A framework for discussion on how to improve prevention, management, and control of hypertension in Canada.
abstract: Increased blood pressure is a leading risk for premature death and disability. The causes of increased blood pressure are intuitive and well known. However, the fundamental basis and means for improving blood pressure control are highly integrated into our complex societal structure both inside and outside our health system and hence require a comprehensive discussion of the pathway forward. A group of Canadian experts was appointed by Hypertension Canada with funding from Public Health Agency of Canada and the Heart and Stroke Foundation of Canada, Canadian Institute for Health Research (HSFC-CIHR) Chair in Hypertension Prevention and Control to draft a discussion Framework for prevention and control of hypertension. The report includes an environmental scan of past and current activities, proposals for key indicators, and targets to be achieved by 2020, and what changes are likely to be required in Canada to achieve the proposed targets. The key targets are to reduce the prevalence of hypertension to 13% of adults and improve control to 78% of those with hypertension. Broad changes in government policy, research, and health services delivery are required for these changes to occur. The Hypertension Framework process is designed to have 3 phases. The first includes the experts' report which is summarized in this report. The second phase is to gather input and priorities for action from individuals and organizations for revision of the Framework. It is hoped the Framework will stimulate discussion and input for its full intended lifespan 2011-2020. The third phase is to work with individuals and organizations on the priorities set in phase 2.
authors.affiliation: Department of Medicine, Libin Cardiovascular Institute of Alberta, University of Calgary, Calgary, Alberta, Canada. ncampbel@ucalgary.ca
authors.forename: Norm
authors.initials: N
authors.lastname: Campbell
authors.forename: Eric R
authors.initials: ER
authors.lastname: Young
authors.forename: Denis
authors.initials: D
authors.lastname: Drouin
authors.forename: Barbara
authors.initials: B
authors.lastname: Legowski
authors.forename: Michael A
authors.initials: MA
authors.lastname: Adams
authors.forename: Judi
authors.initials: J
authors.lastname: Farrell
authors.forename: Janusz
authors.initials: J
authors.lastname: Kaczorowski
authors.forename: Richard
authors.initials: R
authors.lastname: Lewanczuk
authors.forename: Margaret
authors.initials: M
authors.lastname: Moy Lum-Kwong
authors.forename: Sheldon
authors.initials: S
authors.lastname: Tobe
mesh_terms: D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001795:Blood Pressure Determination; D002170:Canada; D003131:Combined Modality Therapy; D004032:Diet; D019468:Disease Management; D019317:Evidence-Based Medicine / Q000458:organization & administration; D015444:Exercise / Q000502:physiology; D005260:Female; D006266:Health Education / Q000458:organization & administration*; D006801:Humans; D006973:Hypertension / Q000453:epidemiology / Q000517:prevention & control* / Q000628:therapy*; D008019:Life Style; D008297:Male; D008875:Middle Aged; D017410:Practice Guidelines as Topic; D011322:Primary Prevention / Q000458:organization & administration; D016730:Program Development; D015397:Program Evaluation; D011634:Public Health; D012720:Severity of Illness Index
chemical_list: D000959:Antihypertensive Agents